• ARIA acquisition value: The transaction secures proprietary ontologies and knowledge graphs that harmonize EHR, disease, and genomic data for clinical decision-making, while integrating ARIA's founders and chief scientists into IKS's AI development.
• TruBridge financial targets: By combining IKS ($364 million revenue) with TruBridge ($347 million), management aims to scale EBITDA from roughly 1,000 crore rupees to 3,000 crore rupees by FY30 and pare down $600 million in assumed debt to around $26 million.
• Growth and deal closure: IKS expects to outpace the 12% industry growth rate as recent contract wins ramp up, with the TruBridge transaction targeted to close in Q2 pending regulatory approvals.
• Addressable market expansion: Acquiring TruBridge expands IKS beyond its core outpatient and physician clinic base into rural and community hospitals, while providing extensive EHR datasets to build AI training models.